Financings in Brief: Hepatix
This article was originally published in The Gray Sheet
Executive Summary
Hepatix: Additional $3 mil. investment is secured from current shareholders including Chase Venture Capital Associates, Alta Partners and Woodland/Essex, the firm reports. Funds will be used for animal testing of the firm's ELAD extracorporeal liver assist device. The privately held company recently received state approval for its San Diego manufacturing facility, paving the way for production of the devices for use in human clinical trials. Studies in humans are anticipated to begin in late 1998, according to the firm...